Jupiter Neurosciences Appoints Ex-White House Advisor, Awards 536,428 Share Options
JUNS•Jupiter Neurosciences appointed health economist Tomas J. Philipson to its board effective June 26, 2026, assigning him to both audit and compensation committees. He received a sign-on option for 90,000 shares and performance-aligned options for 446,428 shares valued at $125,000, tying compensation to long-term stock performance.
1. Board Appointment
Jupiter Neurosciences appointed Tomas J. Philipson, Ph.D., to its board effective June 26, 2026, filling a key leadership role. He will serve on both the Audit and Compensation Committees, strengthening governance as the company advances its clinical pipeline.
2. Dr. Philipson’s Background
Philipson is a former Acting Chairman of the White House Council of Economic Advisers (2019-2020) with senior advisory roles at the FDA and CMS, plus academic tenure at the University of Chicago. His expertise spans health economics, regulatory policy, and pharmaceutical valuation methodologies, supporting strategic decision-making.
3. Equity Compensation
He received an option for 90,000 shares vesting quarterly over 36 months plus performance-aligned options for 446,428 shares valued at $125,000, vesting quarterly over three years. This structure aligns his incentives with long-term shareholder value.
